---
audienceLevel: patient
cancerTypes:
- skin
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Talimogene Laherparepvec - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/talimogenelaherparepvec
version: v1
---

# Talimogene Laherparepvec - NCI

# Talimogene Laherparepvec

Placeholder slot

(tah-LIH-moh-jeen lah-HER-pah-REP-vek)

This page contains brief information about talimogene laherparepvec
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Imlygic

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64ffb680-ea8c-42fc-9649-9e8c0eb77ddb&audience=consumer)

## Use in Cancer

Talimogene laherparepvec
is approved to treat:

- **[Melanoma](/Common/PopUps/popDefinition.aspx?id=45135&version=Patient&language=English)** in the skin and [lymph nodes](/Common/PopUps/popDefinition.aspx?id=45762&version=Patient&language=English) that cannot be removed by surgery. It is used as [local](/Common/PopUps/popDefinition.aspx?id=45755&version=Patient&language=English) treatment in patients whose disease has come back after being treated with surgery.

Talimogene laherparepvec
is also being studied in the treatment of other types of
cancer.

## More About Talimogene Laherparepvec

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/485296) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Talimogene Laherparepvec](https://medlineplus.gov/druginfo/meds/a616006.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Oncolytic Virus Enables the Immune System to Attack Tumors](https://www.cancer.gov/news-events/cancer-currents-blog/2023/oncolytic-virus-blocking-tgf-beta)

[Cancer Treatment Vaccines](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-treatment-vaccines)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Talimogene Laherparepvec](https://www.cancer.gov/research/participate/clinical-trials/intervention/C61314) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
